Symbol="EVAX"
AssetType="Common Stock"
Name="Evaxion Biotech AS"
Description="Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark."
CIK="1828253"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="BREDGADE 34E, COPENHAGEN K, DK"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="28469500"
EBITDA="-24854000"
PERatio="None"
PEGRatio="None"
BookValue="0.344"
DividendPerShare="0"
DividendYield="0"
EPS="-0.96"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.508"
ReturnOnEquityTTM="-1.137"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.96"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="10.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="3.805"
EVToRevenue="-"
EVToEBITDA="-1.322"
Beta="0.45"
num_52WeekHigh="3.1"
num_52WeekLow="0.92"
num_50DayMovingAverage="1.284"
num_200DayMovingAverage="1.585"
SharesOutstanding="27640300"
DividendDate="None"
ExDividendDate="None"
symbol="EVAX"
open="1.05"
high="1.07"
low="0.99"
price="1.03"
volume="60406.00"
latest_trading_day="2023-08-09"
previous_close="0.98"
change="0.05"
change_percent="5.1020%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="57"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="43"
Volume_recent_avg="175108"
Change_recent_avg="0.01"
Delta_recent_avg="0.12"
Variance_recent_avg="0.06"
Change_ratio_recent_avg="-0.44"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="43"
Aroon_momentum_negative="57"
image_negative_thumbnail_id_1="101"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0075.jpeg"
image_negative_thumbnail_id_2="493"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0112.jpeg"
image_neutral_thumbnail_id_1="536"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0063.jpeg"
image_neutral_thumbnail_id_2="566"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_positive_thumbnail_id_1="613"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0095.jpeg"
image_positive_thumbnail_id_2="646"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0062.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
